



NDA 207500/S-005  
NDA 207501/S-004

## SUPPLEMENT APPROVAL

Astellas Pharma US Inc  
Attention: Robert M. Reed  
Senior Director, Regulatory Affairs  
1 Astellas Way  
Northbrook, IL 60062

Dear Mr. Reed:

Please refer to your supplemental new drug applications (sNDAs) dated May 13, 2019, received May 13, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cresemba (isavuconazonium sulfate) capsules, 186 mg (NDA 207500), and Cresemba (isavuconazonium sulfate) for injection, 372 mg (NDA 207501).

These Prior Approval supplemental new drug applications provide for revisions to the prescribing information to comply with the requirements of the Pregnancy and Lactation Labeling Rule. Additionally, the **PATIENT INFORMATION** has been reformatted and revised to align with changes to the **PRESCRIBING INFORMATION**, and minor editorial revisions have been made throughout the **PRESCRIBING INFORMATION**.

### **APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

*{See appended electronic signature page}*

Dmitri Iarikov, MD, PhD  
Deputy Director  
Division of Anti-Infectives  
Office of Infectious Diseases  
Center for Drug Evaluation and Research

#### **ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

DMITRI IARIKOV  
12/09/2019 11:19:12 AM